Today, ASAM released its first clinical guidance for managing intoxication and withdrawal involving medetomidine, an emerging adulterant in the unregulated opioid supply linked to unique and severe symptoms.
In this educational activity, developed in collaboration with PeerView Institute for Medical Education, clinicians will strengthen skills in screening, diagnosis, and early intervention for patients across the AUD severity spectrum >> bit.ly/4e5qThQ